Apellis Pharmaceuticals, Inc.APLSNASDAQ
Loading
EV to Sales: Discounted ValuationCompressed
Percentile Rank58
3Y CAGR-63.8%
5Y CAGR-28.0%
Year-over-Year Change
Enterprise value to sales ratio
3Y CAGR
-63.8%/yr
Annual compound
5Y CAGR
-28.0%/yr
Recent deceleration
Percentile
P58
Within normal range
vs 5Y Ago
0.2x
Contraction
Streak
3 yr
Consecutive declineCompressed
| Period | Value | YoY Change |
|---|---|---|
| 2025 | 3.17 | -38.2% |
| 2024 | 5.13 | -70.3% |
| 2023 | 17.31 | -74.1% |
| 2022 | 66.93 | +25.1% |
| 2021 | 53.50 | +226.2% |
| 2020 | 16.40 | - |
| 2019 | 0.00 | - |
| 2018 | 0.00 | - |
| 2017 | 0.00 | - |
| 2016 | 0.00 | - |